Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

313 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The experience of pregnant women and their families who were infected with covid-19 before vaccination: A qualitative approach within a multicenter study in Brazil.
Soeiro RE, Souza RT, Bento SF, Cecatti JG, Surita FG, Freitas-Jesus JV, Pacagnella RC, Ribeiro-Do-Valle CC, Luz AG, Lajos GJ, Nobrega GM, Griggio TB, Charles CM, Silveira C, Miele MJ, Tedesco RP, Fernandes KG, Martins-Costa SH, Peret FJ, Feitosa FE, Traina E, Cunha Filho EV, Vettorazzi J, Haddad SM, Andreucci CB, Guida JP, Correa Junior MD, Dias MA, Oliveira LG, Melo Junior EF, Luz MGD, Costa ML; REBRACO Study Group. Soeiro RE, et al. Midwifery. 2024 Apr 23;135:104018. doi: 10.1016/j.midw.2024.104018. Online ahead of print. Midwifery. 2024. PMID: 38729000
Effect of 12-week high-intensity interval training on hemodynamic variables at rest and during exercise in patients with obstructive sleep apnoea.
Lins-Filho O, Germano-Soares AH, Aguiar JLP, de Almedia JRV, Felinto EC, Lyra MJ, Leite DB, Drager LF, Farah BQ, Pedrosa RP. Lins-Filho O, et al. Among authors: leite db. J Hypertens. 2024 Apr 1;42(4):742-745. doi: 10.1097/HJH.0000000000003654. Epub 2024 Jan 3. J Hypertens. 2024. PMID: 38230605 Clinical Trial.
Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial.
Tuttle KR, Hauske SJ, Canziani ME, Caramori ML, Cherney D, Cronin L, Heerspink HJL, Hugo C, Nangaku M, Rotter RC, Silva A, Shah SV, Sun Z, Urbach D, de Zeeuw D, Rossing P; ASi in CKD group. Tuttle KR, et al. Lancet. 2024 Jan 27;403(10424):379-390. doi: 10.1016/S0140-6736(23)02408-X. Epub 2023 Dec 15. Lancet. 2024. PMID: 38109916 Clinical Trial.
313 results